EnglishGermanChinese (Simplified)FrenchJapanese


SYNTap™ Biomarker Test helps differentiate dementia types in Alzheimer’s patients.

Using cerebral spinal fluid (CSF), this test precisely identifies the presence of misfolded Synuclein, even in the early stages prior to symptoms.

Studies show up to 50% of Alzheimer’s patients have misfolded Synuclein in their brains, which may affect the course of the disease and how the patients respond to certain drug treatments.


SYNTap Biomarker Test accurately diagnoses Lewy Body Dementia (LBD).

By tracking misfolded Synuclein, this essential test helps doctors accurately diagnose people showing both cognitive and motor symptoms initially.

LBD is a recently discovered brain disease, which sadly until now has only been definitively diagnosed by autopsy. This test is a game-changer.


SYNTap Biomarker Test helps doctors diagnose Parkinson’s Disease (PD).

Doctors have long sought conclusive confirmation when they suspect PD. This biomarker test precisely detects misfolded Synuclein, a biomarker driving PD’s progression.

Our ability to track this biomarker accurately – at early stages – empowers research to race to cures.

Want to learn more about our SYNTap Test? Read the FAQs.

Would you like Amprion to contact a doctor for testing availability? 

REFER A doctor

* A physician must prescribe the SYNTap Test. Use this form to refer a doctor.*

Currently, Amprion offers this test on a self-pay basis. We are also working diligently to establish reimbursement from private insurance providers, Medicare, and Medicaid. The SYNTap Test is available in the US, except Maryland, New York, Pennsylvania, and Rhode Island. We anticipate rollout in these states within the next few months.

Contact Information

Physician's Information

Full Disclosure:  Amprion respects and treats personal information with the utmost confidentiality. We are committed to anonymity and will not sell your personal data to third parties. Therefore, we respectfully ask that you do not enter any personal diagnostic data here.

SYNTap™ Biomarker Test
Frequently Asked Questions

The SYNTap Biomarker Test is a breakthrough test exclusively offered by Amprion. It is not currently covered by private insurance, Medicare, or Medicaid. At present, Amprion does not submit claims to insurance companies. Therefore, patients are responsible for the cost of the test.

During this early release of the SYNTap Test, we are only accepting direct-bill or self-pay patients. For this period, the cost of the test is $1,500.

Medicare does not currently cover the SYNTap Biomarker Test. Medicare patients must complete the Advance Beneficiary Notice (ABN) acknowledging that you are responsible for the cost of the test. The ABN must be signed and sumbited prior to the test being performed.  

The test is currently available throughout the US, except Pennsylvania, Maryland, Rhode Island, and New York. We are working hard to ensure the SYNTap Test is available in all states as soon as possible.

Amprion accepts credit cards, personal checks, and money orders. Patients can make a payment via mail or over the phone. For additional details or questions, please contact: 

Patient Billing Center:
Telephone: 1-858-461-6338 (M-F 9AM – 5PM PST)
Email: Patient.Services@AmprionMe.com

Yes, we offer payment plans and financial assistance. For details, please get in touch with our billing department.

Patient Billing Center:
Telephone: 1-858-461-6338 (M-F 9AM – 5PM PST)
Email: Patient.Services@AmprionMe.com

amprion logo quote solid blue
Do good by doing well, do well by doing good.
Scroll to Top
Share on facebook
Share on twitter
Share on linkedin